Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Mablink Bioscience S.A.S. a biotechnology company developing a pipeline of ADC based on its proprietary PSARlink™ drug-linker technology and Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat cancers with high unmet needs announced that they entered into a Licensing Agreement. Under the terms of the agreement, Emergence Therapeutics will use a PSARlink™ drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

Jack Elands, CEO of Emergence Therapeutics said: “Mablink Bioscience’s technology, PSARlink™, which is based on a hydrophilic linker using a polysarcosine arm, enabled us to design a Nectin-4 ADC loaded with the cytotoxic agent of our choice, whilst retaining the antibody’s pharmacological properties. This technology has the potential to widen the therapeutic index of an ADC and to make our Nectin-4 ADC a best-in-class. The preclinical data we obtained so far are very encouraging in this regard.” Jean-Guillaume Lafay, CEO of Mablink Bioscience added: “We have developed a unique technology that we believe solves the core issue that impaired so many ADC developments. Grafting cytotoxic molecules to an Antibody usually creates a rather hydrophobic ADC, which is correlated with poor pharmacological properties (low drug-exposure and general toxicity issues). While Mablink Bioscience develops its own drug candidates targeting several difficult-to-treat cancers, we are delighted to be joined by Emergence Therapeutics in our effort to develop the 3rd generation of ADCs and to bring new, more efficient, therapeutic options to cancer patients.”

Pursuant to the agreement, Mablink Bioscience is entitled to receive milestone and royalty payments, based on the development of the Nectin-4 ADC.